FR16C1025I1 - Sel de 4-[[4-[[4-(2-Cyanoethenyl)-2,6-dimethylphenyl]amino]-2-Pyrimidinyl]amino]benzonitrile - Google Patents

Sel de 4-[[4-[[4-(2-Cyanoethenyl)-2,6-dimethylphenyl]amino]-2-Pyrimidinyl]amino]benzonitrile

Info

Publication number
FR16C1025I1
FR16C1025I1 FR16C1025C FR16C1025C FR16C1025I1 FR 16C1025 I1 FR16C1025 I1 FR 16C1025I1 FR 16C1025 C FR16C1025 C FR 16C1025C FR 16C1025 C FR16C1025 C FR 16C1025C FR 16C1025 I1 FR16C1025 I1 FR 16C1025I1
Authority
FR
France
Prior art keywords
amino
cyanoethenyl
dimethylphenyl
pyrimidinyl
benzonitrile
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR16C1025C
Other languages
English (en)
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38091637&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR16C1025(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from MYPI20043578A external-priority patent/MY169670A/en
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of FR16C1025I1 publication Critical patent/FR16C1025I1/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Hybrid Cells (AREA)
FR16C1025C 2004-09-02 2016-12-20 Sel de 4-[[4-[[4-(2-Cyanoethenyl)-2,6-dimethylphenyl]amino]-2-Pyrimidinyl]amino]benzonitrile Active FR16C1025I1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
MYPI20043578A MY169670A (en) 2003-09-03 2004-09-02 Combinations of a pyrimidine containing nnrti with rt inhibitors
PCT/EP2004/052028 WO2005021001A1 (en) 2003-09-03 2004-09-03 Combinations of a pyrimidine containing nnrti with rt inhibitors
EP05101467 2005-02-25

Publications (1)

Publication Number Publication Date
FR16C1025I1 true FR16C1025I1 (fr) 2017-02-03

Family

ID=38091637

Family Applications (2)

Application Number Title Priority Date Filing Date
FR16C1025C Active FR16C1025I1 (fr) 2004-09-02 2016-12-20 Sel de 4-[[4-[[4-(2-Cyanoethenyl)-2,6-dimethylphenyl]amino]-2-Pyrimidinyl]amino]benzonitrile
FR16C1023C Active FR16C1023I1 (fr) 2004-09-02 2016-12-20 Sel de 4-[[4-[[4-(2-Cyanoethenyl)-2,6-dimethylphenyl]amino]-2-Pyrimidinyl]amino]benzonitrile

Family Applications After (1)

Application Number Title Priority Date Filing Date
FR16C1023C Active FR16C1023I1 (fr) 2004-09-02 2016-12-20 Sel de 4-[[4-[[4-(2-Cyanoethenyl)-2,6-dimethylphenyl]amino]-2-Pyrimidinyl]amino]benzonitrile

Country Status (21)

Country Link
EP (1) EP1632232B3 (es)
JP (1) JP4912309B2 (es)
CN (1) CN104586850A (es)
AT (1) ATE508748T1 (es)
BR (1) BRPI0514871A (es)
CY (3) CY1112249T1 (es)
DK (1) DK1632232T6 (es)
EA (1) EA013686B1 (es)
ES (1) ES2371442T7 (es)
FR (2) FR16C1025I1 (es)
HK (1) HK1210029A1 (es)
HU (2) HUS1600060I1 (es)
IL (1) IL181650A (es)
LT (2) LTPA2016042I1 (es)
ME (1) ME01246B (es)
MX (1) MX2007002595A (es)
NI (1) NI200700068A (es)
NO (3) NO340654B1 (es)
PT (1) PT1632232E (es)
RS (1) RS51923B2 (es)
SI (1) SI1632232T1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
DK1981506T6 (da) 2006-01-20 2021-06-14 Janssen Sciences Ireland Unlimited Co Langtidsbehandling af hiv-infektion med tcm278
AR065720A1 (es) 2007-03-14 2009-06-24 Tibotec Pharm Ltd Polvos para reconstitucion que comprenden rilpivirina dispersos en ciertos polimeros. uso. proceso.
ME01980B (me) 2010-11-19 2015-05-20 Gilead Sciences Inc Terapeutske kompozicije koje sadrže rilpivirin hcl i tenofovir dizoproksil fumarat
AP2013006779A0 (en) * 2011-04-15 2013-03-31 Emcure Pharmaceuticals Ltd An improved rilpivirine process
WO2013087794A1 (en) 2011-12-14 2013-06-20 Sandoz Ag Polymorph of rilpivirine hydrochloride and its use as antiviral
EP2628732A1 (en) 2012-02-20 2013-08-21 Sandoz AG Novel crystalline form of rilpivirine hydrochloride
EP2604593A1 (en) 2011-12-14 2013-06-19 Sandoz AG Polymorph of Rilpivirine hydrochloride and its use as antiviral
WO2013153161A2 (en) 2012-04-11 2013-10-17 Sandoz Ag Novel polymorph of rilpivirine hydrochloride
WO2013153162A1 (en) 2012-04-11 2013-10-17 Sandoz Ag Polymorph of rilpivirine hydrochloride
CN103570688B (zh) * 2012-07-19 2016-06-08 中国科学院上海药物研究所 2，5-二氨甲基吡嗪类化合物、其药物组合物、制备方法和用途
GR1008965B (el) * 2015-12-02 2017-02-28 Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων Φαρμακευτικο σκευασμα που περιλαμβανει δαρουναβιρη και μεθοδος παρασκευης αυτου
RU2616267C1 (ru) * 2016-01-25 2017-04-13 Закрытое Акционерное Общество "БИОКОМ" Твердая лекарственная форма индинавира немедленного высвобождения и способ ее получения
ES2970870T3 (es) * 2016-10-24 2024-05-31 Janssen Sciences Ireland Unlimited Co Composiciones dispersables
US12011506B2 (en) * 2017-06-30 2024-06-18 Viiv Healthcare Company Combination and uses and treatments thereof
CN114392241B (zh) * 2022-01-10 2023-07-25 安徽贝克生物制药有限公司 一种利匹韦林片及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6307543B1 (en) * 1998-09-10 2001-10-23 Silicon Image, Inc. Bi-directional data transfer using two pair of differential lines as a single additional differential pair
MY169670A (en) * 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
JO3429B1 (ar) * 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
JP4822707B2 (ja) * 2002-08-09 2011-11-24 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ４−［［４−［［４−（２−シアノエテニル）−２，６−ジメチルフェニル］アミノ］−２−ピリミジニル］アミノ］ベンゾニトリルの製造方法
AU2002350719A1 (en) * 2002-11-29 2004-06-23 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
US20070021449A1 (en) * 2003-02-07 2007-01-25 Jan Heeres Pyrimidine derivatives for the prevention of hiv infection

Also Published As

Publication number Publication date
FR16C1023I1 (fr) 2017-02-03
IL181650A0 (en) 2007-07-04
ES2371442T7 (es) 2022-05-12
EP1632232B3 (en) 2022-03-30
CY1112249T1 (el) 2015-12-09
ES2371442T3 (es) 2012-01-02
IL181650A (en) 2012-08-30
RS51923B (en) 2012-02-29
CN104586850A (zh) 2015-05-06
JP4912309B2 (ja) 2012-04-11
PT1632232E (pt) 2011-08-02
LTPA2016042I1 (lt) 2017-01-10
EA013686B1 (ru) 2010-06-30
CY2016050I1 (el) 2017-07-12
NI200700068A (es) 2016-09-29
EA200700536A1 (ru) 2007-08-31
EP1632232A1 (en) 2006-03-08
NO2017065I1 (no) 2017-11-21
CY2016051I1 (el) 2017-07-12
NO20071745L (no) 2007-04-02
LTPA2016043I1 (lt) 2017-01-10
BRPI0514871A (pt) 2008-06-24
MX2007002595A (es) 2007-04-25
SI1632232T1 (sl) 2011-09-30
NO2017063I1 (no) 2017-11-21
ME01246B (me) 2013-06-20
DK1632232T6 (da) 2022-04-19
HUS1600061I1 (hu) 2017-01-30
ATE508748T1 (de) 2011-05-15
RS51923B2 (sr) 2022-05-31
HUS1600060I1 (hu) 2017-01-30
HK1210029A1 (en) 2016-04-15
JP2008511592A (ja) 2008-04-17
NO340654B1 (no) 2017-05-22
EP1632232B1 (en) 2011-05-11
DK1632232T3 (da) 2011-08-22

Similar Documents

Publication Publication Date Title
FR16C1023I1 (fr) Sel de 4-[[4-[[4-(2-Cyanoethenyl)-2,6-dimethylphenyl]amino]-2-Pyrimidinyl]amino]benzonitrile
HK1174922A1 (en) Processes for the preparation of 4-[[4-[[4-(2-cyanoethenyl)-2,6- dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile 4-[[4-[[4-(2-)-2,6-]]-2-]]
ME00191B (me) Farmaceutske kompozicije koje obuhvataju inhibitor hmg reduktaze
PL1632232T3 (pl) Sól 4-[[4-[[4-(2-cyjanoetenylo)-2,6-dimetylofenylo]amino]-2-pirymidynylo]amino]benzonitrylu
WO2009007441A3 (en) Crystalline form of (e) 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2 pyrimidinyl]amino]benzonitrile
UA92467C2 (ru) Гидрохлорид 4-[[4-[[4-(2-цианоэтенил)-2,6-диметилфенил]амино]-2-пиримидинил]амино]бензонитрила
CR9032A (es) Fumarato de 4-((4-((4-(2-cianoetenil)-2,6-dimetilfenil)amino-2- pirimidinil)amino)benzonitrilo
WO2010030201A3 (en) Stable oral pharmaceutical composition containing a pharmaceutically acceptable salt of [(e)-7-[4-(4-fluorophenyl)-6-isopropyl-2- [methyl(methylsulfonyl)amino]pyrimidine-5-yl] (3r, 5s) - 3,5 dihydroxyhept-6- enoic acid
AP2487A (en) Fumarate of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]-amino]-2-pyrimidinyl]amino]benzonitrile
HRP20110563T1 (en) Salt of 4[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile